INVITRO ACTIVITIES OF CEFEPIME ALONE AND WITH AMIKACIN AGAINST AMINOGLYCOSIDE-RESISTANT GRAM-NEGATIVE BACTERIA

被引:17
作者
FUNGTOMC, J
HUCZKO, E
KOLEK, B
THATER, C
KESSLER, RE
机构
[1] Department of Microbiology, B.-M. Squibb Pharm. Res. Inst., Wallingford
关键词
D O I
10.1128/AAC.35.12.2652
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The in vitro activity of cefepime was compared with those of ceftazidime, cefotaxime, and cefpirome against aminoglycoside-resistant gram-negative bacteria. Cefepime was the most active cephalosporin, with a MIC for 90% of strains tested for all non-Pseudomonas aeruginosa species of less-than-or-equal-to 4-mu-g/ml. No cefepime resistance was encountered among members of the family Enterobacteriaceae. Of the 40 aminoglycoside-resistant P. aeruginosa isolates, 15% were resistant to cefepime, compared with 18% for ceftazidime, 30% for cefpirome, and 35% for cefotaxime. Synergism between cefepime and amikacin was observed and occurred most frequently in P. aeruginosa strains resistant to cefepime but susceptible to amikacin. In no case did cefepime and amikacin exhibit antagonism against P. aeruginosa.
引用
收藏
页码:2652 / 2654
页数:3
相关论文
共 17 条
[1]   INVITRO INTERACTIONS OF AMIKACIN AND BETA-LACTAM ANTIBIOTICS AGAINST AMIKACIN-RESISTANT GRAM-NEGATIVE BACILLI [J].
ALVAREZ, S ;
JONES, M ;
HOLTSCLAWBERK, S ;
BERK, SL .
CHEMOTHERAPY, 1988, 34 (02) :107-112
[2]   5-YEAR SURVEILLANCE OF AMINOGLYCOSIDE USAGE IN A UNIVERSITY HOSPITAL [J].
BETTS, RF ;
VALENTI, WM ;
CHAPMAN, SW ;
CHONMAITREE, T ;
MOWRER, G ;
PINCUS, P ;
MESSNER, M ;
ROBERTSON, R .
ANNALS OF INTERNAL MEDICINE, 1984, 100 (02) :219-222
[3]   SYNERGY OF NEW C-3 SUBSTITUTED CEPHALOSPORINS AND TOBRAMYCIN AGAINST PSEUDOMONAS-AERUGINOSA AND PSEUDOMONAS-CEPACIA [J].
CHIN, NX ;
NEU, HC .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1989, 12 (04) :343-349
[4]  
CLARK RB, 1990, MED MICROBIOL IMMUN, V179, P77
[5]   EMERGENCE OF RESISTANCE IN GRAM-NEGATIVE BACTERIA DURING THERAPY WITH EXPANDED-SPECTRUM CEPHALOSPORINS [J].
DWORZACK, DL ;
PUGSLEY, MP ;
SANDERS, CC ;
HOROWITZ, EA .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1987, 6 (04) :456-459
[6]   ACTIVITY OF CEFEPIME AGAINST CEFTAZIDIME-RESISTANT AND CEFOTAXIME-RESISTANT GRAM-NEGATIVE BACTERIA AND ITS RELATIONSHIP TO BETA-LACTAMASE LEVELS [J].
FUNGTOMC, J ;
DOUGHERTY, TJ ;
DEORIO, FJ ;
SIMICHJACOBSON, V ;
KESSLER, RE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (04) :498-502
[7]   RESISTANCE SURVEILLANCE PROGRAMS AND THE INCIDENCE OF GRAM-NEGATIVE BACILLARY RESISTANCE TO AMIKACIN FROM 1967 TO 1985 [J].
GERDING, DN ;
LARSON, TA .
AMERICAN JOURNAL OF MEDICINE, 1986, 80 (6B) :22-28
[8]   ACTIVITY OF CEFEPIME (BMY-28142) AND CEFPIROME (HR 810) AGAINST GRAM-NEGATIVE BACILLI RESISTANT TO CEFOTAXIME OR CEFTAZIDIME [J].
JONES, RN ;
FUCHS, PC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 23 (01) :163-165
[9]   COMPARISON OF A NEW CEPHALOSPORIN, BMY 28142, WITH OTHER BROAD-SPECTRUM BETA-LACTAM ANTIBIOTICS [J].
KESSLER, RE ;
BIES, M ;
BUCK, RE ;
CHISHOLM, DR ;
PURSIANO, TA ;
TSAI, YH ;
MISIEK, M ;
PRICE, KE ;
LEITNER, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 27 (02) :207-216